Aclaris Therapeutics (NASDAQ:ACRS) Earns Buy Rating from HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 333.60% from the stock’s previous close. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.55) EPS.

A number of other analysts also recently issued reports on ACRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Craig Hallum started coverage on shares of Aclaris Therapeutics in a research report on Friday, January 30th. They set a “buy” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Price Performance

ACRS stock opened at $3.69 on Thursday. The stock has a market capitalization of $445.01 million, a P/E ratio of -6.96 and a beta of 0.88. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89. The business has a fifty day moving average price of $3.41 and a 200-day moving average price of $2.77.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million. As a group, analysts anticipate that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Three Bridge Wealth Advisors LLC bought a new stake in shares of Aclaris Therapeutics during the 3rd quarter valued at about $1,358,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $28,000. ProShare Advisors LLC bought a new position in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $26,000. BNP Paribas Financial Markets boosted its holdings in shares of Aclaris Therapeutics by 59.0% in the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after buying an additional 9,894 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Aclaris Therapeutics in the second quarter worth approximately $48,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.